Inexium (Esomeprazole)

Esomeprazole works by binding irreversibly to the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. This inhibition blocks the final step of acid production, leading to a sustained increase in gastric pH and reduced acidity.

The appropriate dose of Inexium is determined by the prescribing healthcare professional based on the patient’s condition, severity, and clinical response. Dosage regimens are individualized and should follow the prescriber’s instructions and local guidelines.

Safety data for esomeprazole in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Inexium, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inexium (esomeprazole) is the S‑enantiomer of omeprazole and generally provides more consistent plasma concentrations and a slightly higher bioavailability. Clinically, it offers comparable acid‑suppression efficacy to other PPIs, with a similar safety profile, but the choice often depends on formulation, dosing convenience and individual patient response.

Inexium should be stored at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided with the product.

Inexium is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of qualified medical personnel. The infusion rate and duration are set by the prescribing clinician according to the patient’s therapeutic needs.

Serious risks include Clostridioides difficile‑associated colitis, acute interstitial nephritis, severe electrolyte disturbances such as hypomagnesemia, and rare allergic reactions like anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, renal impairment and allergic responses during therapy.

Inexium is contraindicated in patients with known hypersensitivity to esomeprazole, other proton pump inhibitors, or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, and it should be avoided in patients where rapid acid suppression is not indicated without a prescriber’s assessment.